Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLYPSO: Early intervention with bimekizumab in plaque psoriasis
2024-514647-29-01Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of bimekizumab in plaque psoriasis (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Primary: PGA at week 16 and week 24 with treatment failure definition. Planned start Dec 2024; status: authorised.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2024-514647-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514647-29-01.